| 张 鹏,乔 晞,乔海燕,王利华,翟志丽.阿魏酸钠联合缬沙坦对糖尿病肾病患者的疗效及对肾脏纤维化的影响[J].,2020,(11):2148-2151 |
| 阿魏酸钠联合缬沙坦对糖尿病肾病患者的疗效及对肾脏纤维化的影响 |
| Effect of Sodium and Valsartan Coadministration on Diabetic Kidney Disease and Renal Fibrosis |
| 投稿时间：2020-02-04 修订日期：2020-02-26 |
| DOI：10.13241/j.cnki.pmb.2020.11.032 |
| 中文关键词: 阿魏酸钠 缬沙坦 糖尿病肾病 肾功能 血糖 肾脏纤维化 |
| 英文关键词: Sodium Ferulate Valsartan Diabetic Nephropathy Renal Function Blood Glucose Renal Fibrosis |
| 基金项目:山西省留学回国人员科技活动择优资助项目（2017-29） |
|
| 摘要点击次数: 703 |
| 全文下载次数: 411 |
| 中文摘要: |
| 摘要 目的：研究阿魏酸钠联合缬沙坦对糖尿病肾病（diabetic kidney disease，DKD）患者的治疗效果及对肾脏纤维化的影响。方法：选择 2017 年 1 月～ 2018 年12 月山西医科大学附属晋中医院收治的 101 例糖尿病肾病患者，随机分为两组。两组均低蛋白饮食，口服他汀类药物调脂，口服降糖药和（或）胰岛素控制血糖。对照组加服缬沙坦8 0 mg/d 治疗，观察组服缬沙坦联合静脉滴注 0.3 g 的阿魏酸钠，每天 1 次。两组均连续治疗1个月。观察两组肾功能指标、血糖指标以及肾脏纤维化指标的变化。结果：治疗后，观察组的治疗总有效率 92.00 %(46/50)，显著高于对照组[68.63%(35/51)](P<0.05)。治疗后，两组患者血清的纤维化相关指标Ⅲ 型前胶原(procollagen type Ⅲ ，PC Ⅲ )和Ⅳ 型胶原(typeⅣ Collagen，C Ⅳ )均明显降低(P<0.05)，且观察组的明显低于对照组(P<0.05)；治疗后，两组的空腹血糖(fasting plasma glucose，FPG)、餐后 2 h 血糖(2 h plasma glucose，2 h PG)、血尿素氮(blood urea nitrogen，BUN)、血肌酐(serum creatinine，SCr)、β2- 微球蛋白(β2-Microglobulin，β2-MG)、24 h 尿白蛋白排泄率(24 h urine microalbumin excretion，24 h UAER)均明显降低(P<0.05)，且观察组的指标均显著低于对照组(P<0.05)，两组肾小球滤过率(GFR)增高(P<0.05)，且观察组指标明显高于对照组(P<0.05)。结论：阿魏酸钠联合缬沙坦对DKD患者有较好的疗效，能明显延缓机体肾脏纤维化的进展速度，进而有效改善肾功能。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of sodium ferulate and valsartan combined therapy on diabetic kidney disease（DKD）and renal fibrosis. Methods: One hundred and one cases of patients with DKD who were treated in Jinzhong Hospital affiliated to Shanxi Medical University from January 2017 to December 2018 were studied. They were divided into two groups randomly. Both groups were treated with low protein diet, statins, oral hypoglycemic drugs and/or insulin to control blood glucose. The control group was also treated with valsartan 80 mg/d. The observation group was given 0.3 g sodium ferulate intravenously once a day in addition to valsartan. Both groups were treated continuously for 1 month. Renal function, blood glucose and index of renal fibrosis were detected. Results: After treatment, the total effective rate in the observation group was 92.00 %(46/50), which was significantly higher than that of the control group[68.63 % (35/51)](P<0.05). After treatment, serum fibrosis related indicators PCⅢ and CⅣ levels in both groups were significantly reduced(P<0.05), and those in the observation group were significantly lower than that of the control group (P<0.05). After treatment, the fasting plasma glucose, 2 h plasma glucose, blood urea nitrogen, serum creatinine, β2-microglobulin and 24 h urine microalbumin excretion of the two groups were significantly reduced (P<0.05), and the changes of the above index in the observation group were more obviously than that of the control group (P<0.05). The GFR level of the two groups were increased (P<0.05), and the changes of the above index in the observation group were more obviously than that of the control group (P<0.05). Conclusion: Sodium ferulate and valsartan combined therapy was effective for the treatment of DKD, and could significantly delay renal fibrosis, and thus protect renal function. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
